SEC Filings | Landos Biopharma

Filing date	Form	Description	View
02/01/21	CORRESP	CORRESP	0001193125-21-024647.pdf 89.2 KB 0001193125-21-024647.rtf 0001193125-21-024647.xls View HTML
01/28/21	CORRESP	CORRESP	0001193125-21-020158.pdf 112.2 KB 0001193125-21-020158.rtf View HTML
02/01/21	CORRESP	CORRESP	0001193125-21-024836.pdf 152.9 KB 0001193125-21-024836.rtf View HTML
02/01/21	CORRESP	CORRESP	0001193125-21-024641.pdf 77.1 KB 0001193125-21-024641.rtf 0001193125-21-024641.xls View HTML
08/11/22	CORRESP	CORRESP	0001193125-22-218093.pdf 0001193125-22-218093.rtf 0001193125-22-218093.xls View HTML
05/16/22	CORRESP	CORRESP	0001193125-22-151650.pdf 0001193125-22-151650.rtf 0001193125-22-151650.xls View HTML
05/18/22	CORRESP	CORRESP	0001193125-22-153928.pdf 0001193125-22-153928.rtf 0001193125-22-153928.xls View HTML
07/24/20	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	0000950123-20-007158.pdf 4.4 MB 0000950123-20-007158.rtf 0000950123-20-007158.xls View HTML
02/03/21	EFFECT	EFFECT	9999999995-21-000415.pdf 72.7 KB 9999999995-21-000415.rtf 9999999995-21-000415.xls View HTML
08/15/22	EFFECT	EFFECT	9999999995-22-002380.pdf 9999999995-22-002380.rtf 9999999995-22-002380.xls View HTML

Data provided by Kaleidoscope.